Axim Biotech

AXIM is a preclinical-stage biopharmaceutical and diagnostics company pioneering the discovery and development of first-in-class targeted small molecule and monoclonal antibody therapies that disrupt the formation of the extracellular matrix to halt tumor cell growth and metastasis.